Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma

被引：0
|
作者：
Mi Na Kim
Seung Min Lee
Jin Sung Kim
Seong Gyu Hwang
机构：
[1] CHA University School of Medicine,Division of Gastroenterology, Department of Internal Medicine, CHA Bundang Medical Center
[2] CHA University,Institute for Clinical Research, CHA Bundang Medical Center
[3] School of Medicine,undefined
[4] CMG Pharmaceutical CO.,undefined
[5] LTD,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; Sorafenib; Dual PI3K/mTOR inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：809 / 817
页数：8
相关论文
共 50 条
  • [31] Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib
    Serova, M.
    Raballand, A.
    Dos Santos, C.
    Riveiro, E.
    Raymond, E.
    Faivre, S.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 113 - 113
  • [32] Discovery and research of a novel dual PI3K/mTOR inhibitor, DS-7423
    Shiose, Yoshinobu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 48P - 48P
  • [33] A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
    Sun, Xin
    Yang, Yang
    Xia, Lulu
    Wang, Shiyu
    Fu, Yuxing
    Zhu, Yuxuan
    Xu, Shan
    Zhu, Wufu
    Zhu, Wufu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [34] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
  • [35] Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
    Chen, Ming-Huang
    Chiang, Kun-Chun
    Cheng, Chi-Tung
    Huang, Shih-Chiang
    Chen, Yeng-Yang
    Chen, Tsung-Wen
    Yeh, Ta-Sen
    Jan, Yi-Yin
    Wang, Hsi-Ming
    Weng, Jiang-Jie
    Chang, Peter Mu-Hsin
    Liu, Chun-Yu
    Li, Chung-Pin
    Chao, Yee
    Chen, Ming-Han
    Huang, Chi-Ying F.
    Yeh, Chun-Nan
    ONCOTARGET, 2014, 5 (09) : 2372 - 2389
  • [36] The dual PI3K/mTOR inhibitor, PI-103, demonstrates therapeutic efficacy in undifferentiated pleomorphic sarcoma
    Zhu, Quansheng
    Xie, Xianbiao
    Nguyen, Theresa
    Bolshakov, Svetlana
    Pollock, Raphael E.
    Lev, Dina Chelouche
    CANCER RESEARCH, 2011, 71
  • [37] Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling
    Dai, Ninggao
    Ye, Ruifan
    He, Qikuan
    Guo, Pengyi
    Chen, Hao
    Zhang, Qiyu
    ONCOLOGY REPORTS, 2018, 40 (06) : 3235 - 3248
  • [38] Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
    Bang, Jieun
    Jun, Mihyeon
    Lee, Soyun
    Moon, Hyuk
    Ro, Simon Weonsang
    PHARMACEUTICS, 2023, 15 (08)
  • [39] Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma
    Doghman, Mabrouka
    Lalli, Enzo
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 364 (1-2) : 101 - 104
  • [40] The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
    Tian, Ling-Yu
    Smit, Daniel J.
    Juecker, Manfred
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
12345